Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as in the Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate, and other cardiovascular indications. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil in patients with paroxysmal supraventricular tachycardia and additional cardiovascular conditions in Greater China. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
IPO Year: 2019
Exchange: NASDAQ
Website: milestonepharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/5/2025 | $5.00 | Buy | H.C. Wainwright |
| 8/22/2024 | $9.00 | Buy | Rodman & Renshaw |
| 6/20/2023 | $8.00 → $4.00 | Buy → Hold | Jefferies |
| 4/22/2022 | $8.00 → $10.00 | Neutral → Overweight | Piper Sandler |
8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
10-Q - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
DEFA14A - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
DEF 14A - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
SCHEDULE 13G/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject)
8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
424B5 - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
H.C. Wainwright resumed coverage of Milestone Pharmaceuticals with a rating of Buy and set a new price target of $5.00
Rodman & Renshaw initiated coverage of Milestone Pharmaceuticals with a rating of Buy and set a new price target of $9.00
Jefferies downgraded Milestone Pharmaceuticals from Buy to Hold and set a new price target of $4.00 from $8.00 previously
Piper Sandler upgraded Milestone Pharmaceuticals from Neutral to Overweight and set a new price target of $10.00 from $8.00 previously
HC Wainwright initiated coverage of Milestone Pharmaceuticals with a rating of Buy and set a new price target of $20.00
H.C. Wainwright initiated coverage of Milestone Pharmaceuticals with a rating of Buy and set a new price target of $20.00